Advanced search×

The WHO Surgical Safety Checklist.

James P Bradley

Med J Aust 193(8):486; author reply 486-7 (2010) PMID 20955133

Version: za2963e q8za3 q8zb0 q8zc3 q8zd7 q8ze1 q8zf0 q8zgf
Buy PDF

Similar articles you may find interesting…

  1. Multicenter Phase II Study of Bendamustine Plus Rituximab in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
    Ken Ohmachi, Nozomi Niitsu, and Michinori Ogura

    J Clin Oncol (2013) PMID 23650408

    lymphopenia (78.0%), neutropenia (76.3%), leukopenia (72.9%), CD4 lymphopenia (66.1%), and thrombocytopenia (22.0%). CONCLUSIONBR is a promising salvage regimen for patients with relapsed or refractory DLBCL after rituximab-containing chemotherapy, warranting further investigation....
    Buy PDF
  2. Hypersensitivity and desensitization to antineoplastic agents: outcomes of 189 procedures with a new short protocol and novel diagnostic too...
    R Madrigal-Burgaleta, M P Berges-Gimeno, and E Alvarez-Cuesta

    Allergy (2013) PMID 23647576

    In the hands of a Desensitization Program, managed by drug desensitization experts, this new protocol has proven an effective therapeutic tool for hypersensitivity to several antineoplastic agents (oxaliplatin, carboplatin, paclitaxel, docetaxel, cyclophosphamide, and rituximab); moreover, it improv...
    Buy PDF
  3. Aspirin desensitisation for Chinese patients with coronary artery disease.
    J Kt Lee, K L Tsui, and S K Li

    Hong Kong Med J (2013) PMID 23650199

    Our results were comparable to those in other reported studies involving other ethnicities. Successful aspirin desensitisation permits patients to pursue long-term double antiplatelet therapy that includes aspirin after percutaneous coronary intervention, and thus allows the use of drug-eluting sten...
    PDF not found